PT Indofarma formerly the State Owned Enterprises (SOEs) and in 2001 began
to go public
PT Indofarma contributing role in the field of education and providing
opportunities to the pharmacy staff / analysts, both at schools and universities
to conduct industrial working practices.
PT. Indofarma (Persero) Tbk producing generic drugs bearing (OGB), trade
names, licenses, traditional medicine and medicinal trademark.
PT.Indofarma (Persero) Tbk., Began to expand the target market by producing
branded generic drugs or generic drugs under the trade name at an
affordable price, which is a government program for the supply of medicines
to the public.
In 2007, PT Indofarma (Persero), Tbk. launched 22 new product items, one of
which is the OND . The rest is OGB (generic drugs bearing) and 12 items Indo
Drug Assault which is a product of OTC (Over The Counter) typical Indofarma
the Company through its Subsbidiary, IGM, cooperates with medical devices
principals to place the devices in hospitals. This system is being managed
under profit-sharing agreement between hospital.
Source : Indofarma-AnnualReport-2014
SWOT Analysis
Strength
Liquidity
Solvability
ACCOUNT RECEIVABLES
COLLECTIBILITY
Company Recomendation
Based on the current condition, companies should make a
plan to improve the expertise to create a new drugs (for
generic) with low cost but improving the quality of the
product.
Make more OND Product in order to decreasing the
dependencies of selling generic brand
Make a huge promotion about launching the new product.
Improve other herbal Production
Based on the Financial condition, PT. Indofarma is improving,
based on the solvability and liquidity ratio, but the growth is
still far behind compared to other companies
Several products were agreed by the decision makers to not
being produced due to negative margin contribution are not
included to the sales forecast.
http://bigcms.bisnis.com/file-data/
1/1419/0e4a11f8_Des15-Indofarma(per
sero)Tbk.pdf
http://www.indonesia-investments.co
m/upload/bedrijfsprofiel/2018/Indof
arma-Annual-Report-2014-Company-Pro
file-INAF-Indonesia-Investments.pdf
Indonesia adalah pasar yang besar
bagi industri farmasi.
http://yunitaardha.blogspot.co.id/20